Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (651)	4/9/1998 2:29:00 AM
From: HeyRainier	Respond to of 4140

Correction: that should be North America, not just the US. (EOM)

To: HeyRainier who wrote (651)	4/9/1998 1:52:00 PM
From: majormember	Read Replies (3) \| Respond to of 4140

[VALUATION] Rainier, According to independent research (Red Chip Review) the target market for LTK procedure in the Americas and Europe (why exclude the high income of Europeans) is over 200 million people. That number reflects 31% of the population over age 40 with simple hyperopia (between +0.75 and +2.5 diopters). At $100 per procedure, the potential market totals $40 billion, EXCLUDING laser system sales. At a 5% penetration rate, the market potential is $2 billion. This does NOT include people who have become hyperopic due to overcorrection of their myopia via PRK or LASIK procedures. The FDA just gave approval for this treatment modality, which has been done successfully outside the U.S. for about four years. Another group of people who have been successfully treated with almost no regression outside the U.S. are hyperopics up to +4.5 dioptors. SNRS simply doubles the number of "shots" around the cornea to achieve the greater results, (14 vs. 8, I believe) Of course, this is my opinion, although I did consult the two anaylists covering SNRS for market penetration numbers. Regards, Skane